Curis doses first five patients in TakeAim CLL combo trial of emavusertib, zanubrutinib
I'm LongbridgeAI, I can summarize articles.Curis has dosed the first five patients in its TakeAim CLL Phase 2 study, evaluating the combination of emavusertib and zanubrutinib for chronic lymphocytic leukemia. The trial targets patients with residual disease despite long-term zanubrutinib therapy to deepen responses and support fixed-duration treatment. Management reported early signs of tolerability and improved responses. Initial results are expected in December 2026.
- Curis dosed the first five patients in its TakeAim CLL Phase 2 study testing emavusertib with zanubrutinib in chronic lymphocytic leukemia. * Initial results have not been presented; early CLL data in 5–10 patients is expected in December 2026. * The study targets patients with residual disease despite long-term zanubrutinib, aiming to deepen responses and support a fixed-duration treatment approach. * Management flagged early signs that the emavusertib-zanubrutinib combination is tolerable, with early indications of improved responses in a small group. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE15746) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)